Nektar Therapeutics (NKTR)

16.99
NASDAQ : Health Technology
Prev Close 16.98
Day Low/High 16.58 / 17.27
52 Wk Low/High 16.56 / 69.76
Avg Volume 2.21M
Exchange NASDAQ
Shares Outstanding 175.27M
Market Cap 2.98B
EPS 4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Interesting NKTR Put And Call Options For March 22nd

Interesting NKTR Put And Call Options For March 22nd

Investors in Nektar Therapeutics saw new options begin trading this week, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.

First Week of NKTR August 2014 Options Trading

First Week of NKTR August 2014 Options Trading

Investors in Nektar Therapeutics saw new options become available this week, for the August 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Short Interest In Nektar Therapeutics Falls 12.5%

Short Interest In Nektar Therapeutics Falls 12.5%

The most recent short interest data has been released by the NASDAQ for the 09/30/2013 settlement date, which shows a 603,483 share decrease in total short interest for Nektar Therapeutics , to 4,224,171, a decrease of 12.50% since 09/13/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Oversold Conditions For Nektar Therapeutics (NKTR)

Oversold Conditions For Nektar Therapeutics (NKTR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer will be watching Washington and a number of stocks.

First Week Of October 19th Options Trading For Nektar Therapeutics (NKTR)

First Week Of October 19th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the October 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new October 19th contracts and identified one put and one call contract of particular interest.

2 Health Care Stocks to Trade for Breakouts

2 Health Care Stocks to Trade for Breakouts

These health care stocks are within range of triggering big breakouts.

Bulls Pile Into Nektar Therapeutics

Bulls Pile Into Nektar Therapeutics

Nektar Therapeutics has been trending higher.

First Week Of NKTR September 21st Options Trading

First Week Of NKTR September 21st Options Trading

Investors in Nektar Therapeutics saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

3 Health Care Stocks Spiking on Big Volume

3 Health Care Stocks Spiking on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Short Interest Drops 20.3% For NKTR

Short Interest Drops 20.3% For NKTR

The most recent short interest data has been released by the NASDAQ for the 05/31/2013 settlement date, which shows a 1,700,119 share decrease in total short interest for Nektar Therapeutics , to 6,690,769, a decrease of 20.26% since 05/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

NKTR Crosses Below Key Moving Average Level

NKTR Crosses Below Key Moving Average Level

In trading on Wednesday, shares of Nektar Therapeutics crossed below their 200 day moving average of $9.06, changing hands as low as $9.05 per share. Nektar Therapeutics shares are currently trading down about 5% on the day.

Nektar Therapeutics Enters Oversold Territory (NKTR)

Nektar Therapeutics Enters Oversold Territory (NKTR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Chaotic Phases Require Patience

Daytrading and overnight flips seem to work best in this algorithm-driven environment, though a few markets show well-organized uptrends.

4 Stocks Under $10 Spiking Higher

4 Stocks Under $10 Spiking Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels

J.P. Morgan Healthcare Confab Live Blog Day Three

J.P. Morgan Healthcare Confab Live Blog Day Three

Live coverage of biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'

A Buysider's Preview of Biotech's Biggest Conference

A Buysider's Preview of Biotech's Biggest Conference

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study

AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study

Nektar and partner AstraZeneca added data to a naloxegol study that could have improperly changed results.

FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs

FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs

Drugs from Salix Pharma, Nektar Therapeutics and Cubist Pharma may be forced into long delays by FDA's request for heart-safety data.

21 Most Volatile Biopharma Stocks Closing Out 2012

21 Most Volatile Biopharma Stocks Closing Out 2012

These biopharma firms will be announcing FDA drug approval decisions and important clinical trial results.

5 Biotech Stocks Poised for Breakouts

5 Biotech Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Nektar Therapeutics Is a Short

Nektar Therapeutics Is a Short

Investor Martin Shkreli believes Nektar's constipation drug is a bust and the stock is a good short.

5 Stocks Poised for Big Breakouts

5 Stocks Poised for Big Breakouts

These stocks look ready to break out and trade higher from current levels.

Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript

Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript

Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript

Disappointment Sinks In

The market is rolling over following initial confusion over the Supreme Court's Obamacare decision.

22 Biopharma Stocks With Breakout Potential in 2012

22 Biopharma Stocks With Breakout Potential in 2012

TheStreet's Adam Feuerstein has compiled a list of drugs with crucial, stock-moving clinical trial catalysts for the remainder of 2012.

Signs Point to MAP Pharma Drug Rejection

Signs Point to MAP Pharma Drug Rejection

FDA regulators have likely derailed MAP Pharma's plans to market an inhaled migraine drug known as Levadex.

TheStreet Quant Rating: D (Sell)